| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yuki Mukai, Robert Lupinacci, Stephen Marder, Linda Snow-Adami, Tiffini Voss, Sean M Smith, Michael F Ega. Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial. Schizophrenia research. vol 270. 2024-06-08. PMID:38851166. |
effects of pde10a inhibitor mk-8189 in people with an acute episode of schizophrenia: a randomized proof-of-concept clinical trial. |
2024-06-08 |
2024-06-11 |
Not clear |
| Yuki Mukai, Robert Lupinacci, Stephen Marder, Linda Snow-Adami, Tiffini Voss, Sean M Smith, Michael F Ega. Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial. Schizophrenia research. vol 270. 2024-06-08. PMID:38851166. |
pde10a inhibition represents a potential mechanism for treating schizophrenia. |
2024-06-08 |
2024-06-11 |
Not clear |
| Yuki Mukai, Robert Lupinacci, Stephen Marder, Linda Snow-Adami, Tiffini Voss, Sean M Smith, Michael F Ega. Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial. Schizophrenia research. vol 270. 2024-06-08. PMID:38851166. |
we evaluated the pde10a inhibitor mk-8189 for treating schizophrenia. |
2024-06-08 |
2024-06-11 |
Not clear |
| Mark E Layton, Jeffrey C Kern, Timothy J Hartingh, William D Shipe, Izzat Raheem, Monika Kandebo, Robert P Hayes, Sarah Huszar, Donnie Eddins, Bennett Ma, Joy Fuerst, Gordon K Wollenberg, Jing Li, Jeff Fritzen, Georgia B McGaughey, Jason M Uslaner, Sean M Smith, Paul J Coleman, Christopher D Co. Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia. Journal of medicinal chemistry. 2023-01-10. PMID:36624931. |
discovery of mk-8189, a highly potent and selective pde10a inhibitor for the treatment of schizophrenia. |
2023-01-10 |
2023-08-14 |
Not clear |
| Manabu Kubota, Keisuke Takahata, Kiwamu Matsuoka, Yasunori Sano, Yasuharu Yamamoto, Kenji Tagai, Ryosuke Tarumi, Hisaomi Suzuki, Shin Kurose, Shinichiro Nakajima, Hiroki Shiwaku, Chie Seki, Kazunori Kawamura, Ming-Rong Zhang, Hidehiko Takahashi, Yuhei Takado, Makoto Higuch. Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia. Schizophrenia bulletin. 2022-12-02. PMID:36458958. |
therapeutic pde10a inhibition effects on schizophrenia have been reported previously, but the status of this molecule in the living patients with schizophrenia remains elusive. |
2022-12-02 |
2023-08-14 |
Not clear |
| Manabu Kubota, Keisuke Takahata, Kiwamu Matsuoka, Yasunori Sano, Yasuharu Yamamoto, Kenji Tagai, Ryosuke Tarumi, Hisaomi Suzuki, Shin Kurose, Shinichiro Nakajima, Hiroki Shiwaku, Chie Seki, Kazunori Kawamura, Ming-Rong Zhang, Hidehiko Takahashi, Yuhei Takado, Makoto Higuch. Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia. Schizophrenia bulletin. 2022-12-02. PMID:36458958. |
therefore, this study aimed to investigate the central pde10a status in patients with schizophrenia and examine its relationship with psychopathology, cognition, and corticostriatal glutamate levels. |
2022-12-02 |
2023-08-14 |
Not clear |
| Mayasah Al-Nema, Anand Gaurav, Ming Tatt Lee, Patrick Okechukwu, Piyarat Nimmanpipug, Vannajan Sanghiran Le. Evaluation of the acute oral toxicity and antipsychotic activity of a dual inhibitor of PDE1B and PDE10A in rat model of schizophrenia. PloS one. vol 17. issue 12. 2022-12-01. PMID:36454774. |
evaluation of the acute oral toxicity and antipsychotic activity of a dual inhibitor of pde1b and pde10a in rat model of schizophrenia. |
2022-12-01 |
2023-08-14 |
human |
| Xiang Li, Qing Wang, Dianwen Zhang, Di Wu, Ning Liu, Tianli Che. Effects of long-term administration of Q808 on hippocampal transcriptome in healthy rats. Chemical & pharmaceutical bulletin. 2022-07-13. PMID:35831127. |
in addition, q808 decreased the mrna expression of pde10a and drd2, which are known to be closely associated with schizophrenia. |
2022-07-13 |
2023-08-14 |
rat |
| Junhao Huang, Baichun Hu, Ziqi Xu, Yunxia Ye, Huibin Wang, Shuxiang Wang, Zhilong Liu, Jian Wan. Selectivity mechanism of phosphodiesterase isoform inhibitor through in silico investigations. Journal of molecular modeling. vol 28. issue 1. 2021-12-15. PMID:34907481. |
phosphodiesterase (pde) family members act in the degradation of camp and cgmp, among which some isoforms such as pde9a are attracting interest for alzheimer's disease treatment, while pde10a is used as target for treating schizophrenia. |
2021-12-15 |
2023-08-13 |
Not clear |
| Si Chen, Jiawei Chen, Hangchuan Shi, Deanne Mickelsen, Chen Ya. Abstract MP265: The Role Of Phosphodiesterase 10a In Tumor Growth And Doxorubicin-induced Cardiotoxicity. Circulation research. vol 129. issue Suppl_1. 2021-11-04. PMID:34735298. |
its high expression in medium spiny neurons of the human striatum has led to the development of several pde10a inhibitors with the intent to treat various psychiatric/neurodegenerative disorders, such as schizophrenia and huntington's disease. |
2021-11-04 |
2023-08-13 |
mouse |
| Thomas A Macek, Kazunori Suzuki, Karen Asin, Haruhide Kimur. Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor. The international journal of neuropsychopharmacology. vol 23. issue 8. 2021-09-21. PMID:32598478. |
tak-063 exhibited antipsychotic-like effects in animal models; however, the translatability of these models to the clinical manifestations of schizophrenia and the meaningfulness for new targets such as pde10a has not been established. |
2021-09-21 |
2023-08-13 |
Not clear |
| Keita Arakawa, Shunsuke Maehar. Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychotic-like effects without affecting cognitive enhancement and cataleptic effects in rats. Neuropsychopharmacology reports. vol 40. issue 2. 2021-08-16. PMID:32351052. |
phosphodiesterase 10a (pde10a) inhibitors not only have antipsychotic-like effects but also cause cognitive enhancement without affecting extrapyramidal side effects in rodents, suggesting that pde10a may be a novel approach for the treatment of schizophrenia. |
2021-08-16 |
2023-08-13 |
rat |
| Harsh S Amin, Palak K Parikh, Manjunath D Ghat. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress. European journal of medicinal chemistry. vol 214. 2021-04-30. PMID:33581555. |
pde10a plays an important role in the regulation of localization, duration, and amplitude of the cyclic nucleotide signalling within the subcellular domain of these regions, and thereby modulation of pde10a enzyme can give rise to a new therapeutic approach in the treatment of schizophrenia and other neurodegenerative disorders. |
2021-04-30 |
2023-08-13 |
human |
| Harsh S Amin, Palak K Parikh, Manjunath D Ghat. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress. European journal of medicinal chemistry. vol 214. 2021-04-30. PMID:33581555. |
however, no selective pde10a inhibitor is currently available in the market for the treatment of schizophrenia. |
2021-04-30 |
2023-08-13 |
human |
| Harsh S Amin, Palak K Parikh, Manjunath D Ghat. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress. European journal of medicinal chemistry. vol 214. 2021-04-30. PMID:33581555. |
the present compilation concisely describes the role of pde10a inhibitors in the therapy of neurodegenerative disorders mainly in psychosis, the structure of pde10a enzyme, key interaction of different pde10a inhibitors with human pde10a enzyme and recent medicinal chemistry developments in designing of safe and effective pde10a inhibitors for the treatment of schizophrenia. |
2021-04-30 |
2023-08-13 |
human |
| Frank S Menniti, Thomas A Chappie, Christopher J Schmid. PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action? Frontiers in neuroscience. vol 14. 2021-02-10. PMID:33551724. |
disappointingly, pde10a inhibitors from 3 companies failed to evidence antipsychotic activity in patients with schizophrenia to the same extent as standard-of-care d2 antagonists. |
2021-02-10 |
2023-08-13 |
Not clear |
| Frank S Menniti, Thomas A Chappie, Christopher J Schmid. PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action? Frontiers in neuroscience. vol 14. 2021-02-10. PMID:33551724. |
with this in mind, we review the data on pde10a inhibition as a step toward back-translating the limited antipsychotic efficacy of pde10a inhibitors, hopefully to inform new efforts to develop better therapeutics to treat psychosis and schizophrenia. |
2021-02-10 |
2023-08-13 |
Not clear |
| Jonas Persson, K Szalisznyó, G Antoni, A Wall, D Fällmar, H Zora, R Bodé. Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study. European archives of psychiatry and clinical neuroscience. vol 270. issue 4. 2020-11-30. PMID:31119377. |
pharmacological inhibition of phosphodiesterase 10a (pde10a) is being investigated as a treatment option in schizophrenia. |
2020-11-30 |
2023-08-13 |
Not clear |
| Jonas Persson, K Szalisznyó, G Antoni, A Wall, D Fällmar, H Zora, R Bodé. Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study. European archives of psychiatry and clinical neuroscience. vol 270. issue 4. 2020-11-30. PMID:31119377. |
pde10a acts postsynaptically on striatal dopamine signaling by regulating neuronal excitability through its inhibition of cyclic adenosine monophosphate (camp), and we recently found it to be reduced in schizophrenia compared to controls. |
2020-11-30 |
2023-08-13 |
Not clear |
| Jonas Persson, K Szalisznyó, G Antoni, A Wall, D Fällmar, H Zora, R Bodé. Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study. European archives of psychiatry and clinical neuroscience. vol 270. issue 4. 2020-11-30. PMID:31119377. |
here, this finding of reduced pde10a in schizophrenia was followed up in the same sample to investigate the effect of reduced striatal pde10a on the neural and behavioral function of striatal and downstream basal ganglia regions. |
2020-11-30 |
2023-08-13 |
Not clear |